Gyre Therapeutics
GYRE
21 hedge funds and large institutions have $14.3M invested in Gyre Therapeutics in 2024 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 5 closing their positions.
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
31% more funds holding
Funds holding: 16 → 21 (+5)
0.27% more ownership
Funds ownership: 0.79% → 1.07% (+0.27%)
8% less capital invested
Capital invested by funds: $15.6M → $14.3M (-$1.32M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.09M |
| 2 |
Goldman Sachs
New York
|
+$831K |
| 3 |
Jane Street
New York
|
+$551K |
| 4 |
State Street
Boston,
Massachusetts
|
+$472K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$472K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parallax Volatility Advisers
San Francisco,
California
|
-$511K |
| 2 |
Renaissance Technologies
New York
|
-$439K |
| 3 |
BlackRock
New York
|
-$187K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$54K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$9.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Acadian Asset Management
Boston,
Massachusetts
| – | +$18 | +1 | New |
|
GYRE Hedge Fund Activity: Q1 2024 in Review
21 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2024, worth a combined $14.3M — down 8.5% from $15.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new GYRE positions and 5 closed out — a net gain of 5 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $1.09M. The largest seller was Parallax Volatility Advisers, exiting entirely with an estimated $511K sold.
- 21 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2024, up from 16 in Q4 2023.
- Funds reported $14.3M of Gyre Therapeutics stock for Q1 2024, down 8.5% quarter-over-quarter.
- 10 funds opened new Gyre Therapeutics positions in Q1 2024 and 5 closed out, a net change of +5 holders.
- The largest Gyre Therapeutics buyer in Q1 2024 was Millennium Management, an estimated $1.09M added.
- The largest Gyre Therapeutics seller in Q1 2024 was Parallax Volatility Advisers, an estimated $511K sold.
Based on aggregated 13F filings for Q1 2024.